, all patients with metastatic NSCLC referred for first oncological evaluation at 4 Hospitals in Brazil were identified by electronic database and included in the analysis. Main eligibility criteria used in first-line phase 3 immunotherapy trials were selected to be evaluated. OS was estimated by Kaplan-Meier curves. Cox proportional hazards model was performed to identify factors associated with survival. All statistical analyses were performed using SAS 9.4. Results: 537 patients were included in this analysis. Mean age was 62.73 6 10.47 years, 57.3% male and 67.0% had adenocarcinoma. 332 (61.8%) patients didn't meet one or more eligible criteria. Patients with ECOG PS 2 and/or active brain metastasis accounted alone for 78.3% of non-eligibility cases. The median OS after the diagnosis of metastatic disease was 7.56 (95% CI: 6.37 to 9.59) months in the non-eligible group and 14.55 (95% CI: 12.16 to 18.23) in the eligible group. Logrank test detected a statistically significant difference between the survival curves in both groups (p ¼ 0.0001). The hazard ratio (HR) of 1.778 (95% CI: 1.425 -2.217) to mortality reflects worse prognostic features in non-eligible group. Also, Logrank test detected a statistically significant difference between the survival curves of ECOG 0-1 and ECOG 2-4 (HR 2.313 95% CI: 1.839 -2.909 p < 0.0001) and histology, with a HR of 1.479 (95% CI: 1.135 -1.927 p ¼ 0.0036) in favor of adenocarcinoma. Median OS in ECOG 0-1 group was 13.17 months (95% CI: 11.89 -15.05) and in ECOG 2-4 was 6.05 months (95% CI: 4.67 -6.77). Median OS in Adenocarcinoma group was 12.48 months (95% CI: 9.63 -13.83) and in Squamous cell was 6.51 months (95% CI: 5.29 -11.17). Conclusions: A significant part of real life Brazilian NSCLC population doesn't fit the strict selection criteria specified by clinical trials. As soon as the experience and safety with this treatment improves, is desirable that future trials admits patiets more representative of real world NSCLC population. Legal entity responsible for the study: J. Cé Coelho. Background: Nivolumab, Pembrolizumab and Ipilimumab monotherapy has shown survival benefits in patients (pts) with melanoma, kidney, lung and head-neck cancer. The aim of this study is to evaluate safety and treatment compliance in terms of delays in the administration or withdrawal of drugs due to toxicity, according to disease and clinical characteristics of pts in clinical practice. Methods: In this retrospective study, data were evaluated on pts in the Reggio Emilia Provincial Oncology Network who were treated for solid metastatic tumors with Nivolumab, Pembrolizumab and Ipilimumab monotherapy in clinical practice. The pts included in the study had received at least 1 dose of therapy by December 2017 and were monitored for adverse events (AE) using Common Terminology Criteria for Adverse Events (v. 4.1). Results: A total of 92 pts were analyzed, of which 42 with lung cancer, 35 with melanoma, 12 with kidney cancer and 3 with head-neck cancer. Sixty-five pts (71%) were treated with Nivolumab, 17% with Pembrolizumab and 12% with Ipilimumab. Overall, 36 pts (39%) experienced an immunorelated adverse event (iAE) of any grade; 33/92 pts (36%) presented a G1-2 iAEs, while only 7% had a G3-4. Out of the 92 pts, the immunotherapy of 17% was delayed due to toxicity, but only 5% of pts discontinued treatment due to iAEs. No statistically significant differences in PFS (9.5 vs. 5.9 months, p ¼ 0.12) and OS (21.9 vs. 12.2 months, p ¼ 0.15) were found between pts who experienced iAEs and those who did not. Cox regression was performed for PFS and OS using sex, performance status (PS), comorbidities, presence of brain metastases, number of previous lines of therapy, number of metastatic sites and age as covariates. For both, only PS (1-2) significantly correlates with poor PFS and OS with respect to PS 0 (p < 0.001).
Background: Nivolumab, Pembrolizumab and Ipilimumab monotherapy has shown survival benefits in patients (pts) with melanoma, kidney, lung and head-neck cancer. The aim of this study is to evaluate safety and treatment compliance in terms of delays in the administration or withdrawal of drugs due to toxicity, according to disease and clinical characteristics of pts in clinical practice. Methods: In this retrospective study, data were evaluated on pts in the Reggio Emilia Provincial Oncology Network who were treated for solid metastatic tumors with Nivolumab, Pembrolizumab and Ipilimumab monotherapy in clinical practice. The pts included in the study had received at least 1 dose of therapy by December 2017 and were monitored for adverse events (AE) using Common Terminology Criteria for Adverse Events (v. 4.1) . Results: A total of 92 pts were analyzed, of which 42 with lung cancer, 35 with melanoma, 12 with kidney cancer and 3 with head-neck cancer. Sixty-five pts (71%) were treated with Nivolumab, 17% with Pembrolizumab and 12% with Ipilimumab. Overall, 36 pts (39%) experienced an immunorelated adverse event (iAE) of any grade; 33/92 pts (36%) presented a G1-2 iAEs, while only 7% had a G3-4. Out of the 92 pts, the immunotherapy of 17% was delayed due to toxicity, but only 5% of pts discontinued treatment due to iAEs. No statistically significant differences in PFS (9.5 vs. 5.9 months, p ¼ 0.12) and OS (21.9 vs. 12.2 months, p ¼ 0.15) were found between pts who experienced iAEs and those who did not. Cox regression was performed for PFS and OS using sex, performance status (PS), comorbidities, presence of brain metastases, number of previous lines of therapy, number of metastatic sites and age as covariates. For both, only PS (1-2) significantly correlates with poor PFS and OS with respect to PS 0 (p < 0.001).
Conclusions:
The data supports the use of immune checkpoint-inhibitors in pts treated in clinical practice with different solid tumors. These treatments are suitable for elderly pts with multiple comorbidities, pts with brain metastases and heavily pretreated pts. However, the use of these drugs should be evaluated with caution in pts with poor PS. Legal entity responsible for the study: Oncology Unit, AUSL IRCCS Reggio Emilia. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Patients included in the analysis had an ECOG performance status 0-1. Twelve patients were treated with combo regimens (including a backbone of an anti-PD1 in combination with a new generation immune-checkpoint inhibitor) and 9 with monotherapy. Only 2 patients, one treated with combo and one with monotherapy, experienced a grade 3 immuno-related toxicity leading to treatment discontinuation: an autoimmune thyroiditis in one case and an autoimmune hepatitis, histologically proved, in the other one. The most common adverse event (AE) was G1-G2 fatigue that occurred in 33% of patients. Immuno-related AEs of any grade were observed in 22% of patients treated with monotherapy compared to 33% in the combo group. Three out of 9 patients treated with monotherapy had a partial response or a stable disease with a DCR of 33%, whereas in the combo group the observed DCR was 66%. Differences were not statistically significant between the two groups for neither toxicity nor efficacy (p value 0.65 and 0.19, respectively). No complete response was observed. Conclusions: Our results suggest that immunotherapy is an effective and well tolerated treatment for older patients with solid tumors. Legal entity responsible for the study: The authors. Background: Metastatic triple negative breast cancer has poor prognosis and limited treatment options. Immunotherapy with anti-PD-L1 monoclonal antibodies has shown promising results in several types of cancer including triple negative breast cancer. We have initiated a clinical trial to test the safety and efficacy of a combination of the investigational anti-PD-L1 monoclonal antibody durvalumab and paclitaxel for the treatment of metastatic breast cancer. The rationale behind this trial is that treatment with paclitaxel correlates with development of tumor infiltrating lymphocytes (Demaria et al. 2001; Sardella et al. 2006) , and the upregulation of PD-L1 on tumor cells. On the other hand, response to targeted anti-PD-L1 therapy correlates with the level of expression of PD-L1 on tumor cells and the pre-existing tumor immunity like CD8þ infiltrating cells and type I helper CD4þ activated lymphocytes (Herbst, Soria et al. 2014 ). In addition, PD-L1 has anti-apoptotic function that its blockade will synergize with the apoptotic effect of chemotherapeutic agents like paclitaxel. Therefore, the combination of these two agents is likely to be synergistic. Trial design: The treatment is designed to start with one cycle of paclitaxel alone to enhance the immunogenicity and immune cell infiltration followed by the combination of the two agents. Paclitaxel will be delivered weekly on days 1, 8 and 15 of each 28 days cycle while Durvalumab will be given every two weeks (Days 1 and 15 of each cycle). Paclitaxel is given for 6 cycles only while Durvalumab is given until disease progression, or unacceptable toxicity. The primary endpoint of the study is to measure safety and tolerability of the combination while the secondary endpoints include efficacy monitoring. 
